2014-10-30 Seong-Eui Hong. Background 1987 2002 2005 2007 2012 2013.

Slides:



Advertisements
Similar presentations
p53 Revealed character as a tumor suppressor gene in 1989.
Advertisements

Cancer-inducing genes - CRGs (cooperation response genes) Paper Presentation Nadine Sündermann.
An introduction to CRISPR gene engineering
Next lecture:techniques used to study the role of genes in develpoment Random genetics followed by screening Targeted mutagenesis (gene knockout) Transgenic.
Luke A. Gilbert, Max A. Horlbeck, Britt Adamson, Jacqueline E
 MicroRNAs (miRNAs) are a class of small RNA molecules, about ~21 nucleotide (nt) long.  MicroRNA are small non coding RNAs (ncRNAs) that regulate.
General Microbiology (Micr300) Lecture 11 Biotechnology (Text Chapters: ; )
Genetic Engineering: Some Basic Concepts. DNA: The Information Carrier.
Chapter 9 – DNA-Based Information Technologies
TYPES OF CLONING VECTORS
Restriction Nucleases Cut at specific recognition sequence Fragments with same cohesive ends can be joined.
CONTEXT SPECIFIC ROLE OF DEUBIQUITYLASE ENZYME, USP9X, IN HEAD AND NECK CANCER Devathri Nanayakkara Eskitis Institute for Drug Discovery Griffith University.
DNA Chips Attach DNA to tiny spots on glass slides (i.e., chip). Hybridize fluorescently-labeled DNA probes to chip. Detect hybridization to different.
BRG-1 in Cancer BRG-1 is an ATPase subunit of the SWI/SNF class of chromatin remodeling complexes It has been found mutated in a number of cancer cell.
Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A.
FIGURE 7.1. Synthesis of a double-stranded DNA molecule.
1 Jin-Soo Kim Dept. of Chemistry, Seoul National Univ. Center for Genome Engineering, Institute for Basic Science Genome Editing: Challenges and Opportunities.
Lecture-7 Genome editing CRISPR
GENE THERAPY.
Maimona Saeed Ph. D Scholar Department of Botany
Inducing and expanding regulatory T cell populations by foreign antigen Karsten Kretschmer NATURE IMMUNOLOGY 2005; 6:1219.
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
What is phage display? An in vitro selection technique using a peptide or protein genetically fused to the coat protein of a bacteriophage.
National Postdoc Appreciation Week
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Use of CRISPR/Cas to edit the Arabidopsis Na+/H+ Antiporter NHX1
Pluripotent stem cell based gene therapy for hematological diseases
Lecture – FALL 2017 Modern methods in Molecular Biology
Volume 152, Issue 5, Pages (April 2017)
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
by Samuel D. Perli, Cheryl H. Cui, and Timothy K. Lu
Figure 2 Use of CRISPR/Cas9 for genome editing
Volume 12, Issue 10, Pages (September 2015)
Volume 23, Issue 5, Pages (May 2018)
Molecular Therapy - Nucleic Acids
Gaelen T. Hess, Josh Tycko, David Yao, Michael C. Bassik 
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Volume 9, Issue 4, Pages (October 2017)
Research Techniques Made Simple: The Application of CRISPR-Cas9 and Genome Editing in Investigative Dermatology  Joan Ramon Guitart, Jodi L. Johnson,
Mouse Genome Engineering via CRISPR-Cas9 for Study of Immune Function
Volume 22, Issue 1, Pages (January 2018)
Volume 13, Issue 2, Pages (February 2006)
Volume 7, Issue 3, Pages (September 2016)
Therapeutic editing of hepatocyte genome in vivo
USH2A Gene Editing Using the CRISPR System
RNA-Guided Genome Editing in Plants Using a CRISPR–Cas System
CRISPR: What is it? Biotech Ethics, Fall ‘18.
Andrew R. Bassett, Charlotte Tibbit, Chris P. Ponting, Ji-Long Liu 
Volume 154, Issue 6, Pages (September 2013)
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9
Amelioration of HB in F9 mutant mice through naked DNA injection of Cas9 components Amelioration of HB in F9 mutant mice through naked DNA injection of.
Volume 9, Issue 4, Pages (November 2014)
Volume 25, Issue 1, Pages (January 2017)
William T. Hendriks, Curtis R. Warren, Chad A. Cowan  Cell Stem Cell 
Expanding the Range of CRISPR/Cas9 Genome Editing in Rice
Volume 19, Issue 3, Pages (September 2016)
CRISPR-Based Technologies for Metabolic Engineering in Cyanobacteria
Volume 26, Issue 6, Pages (June 2018)
Ciaran M Lee, Thomas J Cradick, Gang Bao  Molecular Therapy 
Natalay Kouprina, Vladimir Larionov 
CRISPR/Cas9: Transcending the Reality of Genome Editing
Fig. 4 Gene disruption via chip.
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours By: Anh Pham.
Chemical Biology Approaches to Genome Editing: Understanding, Controlling, and Delivering Programmable Nucleases  Johnny H. Hu, Kevin M. Davis, David R.
Volume 10, Issue 8, Pages (March 2015)
Molecular Therapy - Nucleic Acids
Volume 26, Issue 11, Pages (November 2018)
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off- target Effects in Genome Editing  Ciaran M Lee, Thomas J Cradick,
Presentation transcript:

Seong-Eui Hong

Background

Identification of palindromic and repetitive sequence

Study on the repetitive DNA sequence

Suggestion of the role in cell immunity

Experimental confirmation of adaptive immunity

Mechanisms of CRISPR in adaptive immunity Figure from tracrRNA: trans-acting crRNA

Genome editing using CRISPR

Introduction Aim: Generation of cancer model using CRISPR in mice Target gene: 1)Pten 2)p53 3)beta-catenin

Generation of Pten mutations in adult animals using CRISPR Pten: negative regulator of PI3K/Akt Step1: cloning of pX330 vector co-expressing an sgRNA targeting Pten (sgPten) and Cas9 Step2: in vitro mutation in mouse 3T3 cell using sgPten Step3: in vivo delivery of luciferase plasmid DNA using hydrodynamic tail-vein injection, which can deliver DNA to 20% of hepatocytes Step4: in vivo delivery sgPten and sgGFP in FVB mice during 2 weeks

Result: delivery of sgPten 3.36% hepatocytes with (-) Pten staining 0.4% hepatocytes with intermediate Pten staining (=heterozygous mutation) Elevated staining of pAkt in sgPten mice Oil red O staining indicates lipid accumulation in sgPten mice, which is a known phenotype in Pten mutation in liver Conclusion: in vivo CRISPR-mediated genome editing was able to generate Pten (-) cells in the liver, mimicking liver-specific conditional deletion of Pten in mice

Intermediate loss of Pten

Question: Loss of Pten is due to CRISPR-mediated mutation? Method: Deep sequencing 2.66% of the reads had indels in Pten locus 0.56% indels in sgGFP Most of variants were predicted to cause frameshift mutations 1~2bp indels cause the disruption of the Pten reading frame These indels were at the predicted sgPten induced Cas9 cutting site Whereas the indels in sgGFP distributes randomly Pten loss (scored by IHC) strongly correlated with the Pten indels Conclusion: These data indicate that for most cells, expression of the sgPten vector results in mutation of Pten

Question: long-term phenotype following sgPten treatment? Method: Analysis the livers from 3 sgPten-treated mice at 4 months Lipid accumulation Pten loss Elevated pAkt No induction of p53 despite the activation of pAkt No tumor up to 4 months

Question: off-target? Recent studies identified that Cas9 can tolerate mismatches between sgRNA and genomic DNA depending on the sgRNA sequence and the position of the mismatches Question: potential off-target effects of sgPten in the liver? Method: 1)Prediction of sgPten off-target sites using a published prediction tool 2)Amplification of the Pten locus and the top four potential off-target sites using Surveyor assay Result: There were no Surveyor nuclease cutting, indicating that the frequency of off-target editing is below the limit of detection of this assay

Test of a nickase version of Cas9 Cas9 generates double strand breaks Cas9(D10A) makes single-strand DNA (ssDNA) breaks and was reported to have further reduced levels of off-target effects

Test of a nickase version of Cas9 By deep sequencing, 2.76% indels at the Pten locus compared to 0.26% in sgGFP-treated mice were observed Pten (-) cells were observed

Generation of p53 mutations in adult animals using CRISPR 6.061% of indels in p53 was observed No tumor up to 3 months

Co-injected sgPten and sgp % for Pten and 6.46% for p53 At 3 months post-injection, all 5 mice developed liver tumors with bile duct differentiation features Tumors were positive for cytokeratin 19, a marker of bilinear lineage cells bi-allelic mutations of both genes

Question: Can CRISPR be used to directly introduce gain of-function mutations? Target: Ctnnb1 gene, which encodes  -catenin, a transcription factor in the Wnt signalling pathway that is frequently mutated in liver cancer Phosphorylation at four ser/thr results in the degradation of Ctnnb1 Method: co-injection of two pX330 plasmids carrying i) sgRNA targeting Ctnnb1 and ii) 200 nt ssDNA oligonucleotide containing four point mutation in five mice injected with sg  catenin and ssDNA, 0.5% of hepatocytes exhibited nuclear  -catenin Accumulation of  -catenin was associated with increased levels of glutamine synthetase, a  -catenin target gene

Targeting of  -catenin Reduced level of p-  -catenin Nuclear accumulation of  -catenin As a result of deep sequencing, small but detectable percentage of sequencing reads contained the four ‘G’ point mutations present in the ssDNA Conclusion: These data demonstrate that CRISPR system can be used to directly induce gain-of-function mutation or other substitutions via homologous recombination in vivo

Conclusion The authors illustrate the potential to directly disrupt tumor suppressor genes and generate point mutations in oncogenes in adult mouse liver using the CRISPR/Cas system This approach generated compound Pten and p53 indels at low frequency but was sufficient to induce multifocal tumors More efficient delivery techniques, such as adenovirus or adeno-associated virus, more potent sgRNAs, and longer homologous recombination templates might also improve the overall efficiency of this method and expand the range of tissue that could be targeted Consistent with recent studies showing that long-term Cas9/sgRNA expression is not toxic in cells